Wren Therapeutics
Gustavo Antonio Urrutia is a Platform Scientist at Shift Bioscience since May 2024 and a Visiting Scientist at the University of Cambridge, actively contributing to Alzheimer's Disease and Amyotrophic Lateral Sclerosis-related projects. Previously, Gustavo held the position of Principal Scientist at WaveBreak, leading cell platform initiatives and developing hiPSC-based models for neurodegenerative disease drug discovery. Gustavo's experience includes roles as Senior Scientist and Scientist at Evotec, where significant advancements in Huntington's disease models were made. A Postdoctoral Researcher at the Max-Planck Institute of Immunobiology and Epigenetics, Gustavo focused on Stem Cell differentiation and utilized CRISPR-Cas9 technologies. Gustavo holds a PhD in Developmental Biology from The University of Freiburg, an MSc in Cell Biology from The University of Manchester, and a BSc in Pharmaceutical and Biological Chemistry from Universidad Nacional Autónoma de México.
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.